Integrated Diagnostics Holdings's EBIT per Share for the
three
months ended in Mar. 2026 was $0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.02.
During the past 12 months, the average EBIT per Share Growth Rate of Integrated Diagnostics Holdings was -32.60% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 9.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -19.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 1.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Integrated Diagnostics Holdings's EBIT per Share or its related term are showing as below:
LSE:IDHC'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -45.2 Med: 5 Max: 55.2
Current: 9.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Integrated Diagnostics Holdings was 55.20% per year. The lowest was -45.20% per year. And the median was 5.00% per year.
LSE:IDHC's 3-Year EBIT Growth Rate is ranked worse than 53.57% of 168
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.1
vs LSE:IDHC: 9.30
Integrated Diagnostics Holdings (LSE:IDHC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Integrated Diagnostics Holdings EBIT per Share Related Terms
Integrated Diagnostics Holdings EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Diagnostics Holdings EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Diagnostics Holdings (LSE:IDHC) has a EBIT per Share of $0.02 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Integrated Diagnostics Holdings and its competitors. According to the industry distribution chart, Integrated Diagnostics Holdings ranks #90 out of 168 companies in the Medical Diagnostics & Research industry, placing it in the top 53.6%.
Is Integrated Diagnostics Holdings' EBIT per Share too high?
Integrated Diagnostics Holdings' current EBIT per Share is $0.02. The Medical Diagnostics & Research industry median EBIT per Share is 13.10. Integrated Diagnostics Holdings' value of $0.02 is 99.8% below this industry median. Based on the distribution chart, Integrated Diagnostics Holdings ranks #90 out of 168 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Integrated Diagnostics Holdings has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integrated Diagnostics Holdings ranks #90 out of 168 companies for EBIT per Share. This places Integrated Diagnostics Holdings in the lower half of its industry. The industry median EBIT per Share is 13.10. Integrated Diagnostics Holdings' value of $0.02 is 99.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.10, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrated Diagnostics Holdings's current EBIT per Share of $0.02 is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Integrated Diagnostics Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Diagnostics Holdings's current EBIT per Share is $0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.59, compared to a current price of $0.50 — trading 14.9% below its estimated fair value. The current EBIT per Share is $0.02 and 99.8% below the Medical Diagnostics & Research industry median of 13.10. Integrated Diagnostics Holdings' overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current EBIT per Share is $0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued.
The current stock price of $0.50 is trading 14.9% below its estimated GF Value™ of $0.59.
GuruFocus considers Integrated Diagnostics Holdings to be Modestly Undervalued.
Key valuation signals for LSE:IDHC:
EBIT per Share: $0.02
GF Value™: $0.59 vs. price of $0.50 (14.9% below fair value)
Industry Position: 99.8% below the Medical Diagnostics & Research median (#90 of 168)
No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Diagnostics Holdings Business Description
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
59GF Score
Get the complete analysis for LSE:IDHC
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IDHC has been successfully added to your 
